Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial https://www.nature.com/articles/s41467-025-59279-z
Discover the world at Altruu, The Discovery Engine
Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial https://www.nature.com/articles/s41467-025-59279-z